Novanta, the Massachusetts-based maker of precision photonics and motion components, has agreed to acquire Riverpoint Medical for $1.2 billion in upfront cash plus a $250 million milestone payment, in a deal that pushes the company squarely into minimally invasive surgical consumables. Announced on June 8, 2026, the transaction marks one of the year's larger mid-cap medtech acquisitions and reshapes Novanta's revenue mix toward durable, recurring demand.
Why Riverpoint Matters
Portland, Oregon-based Riverpoint Medical is a category leader in implantable surgical fibers, coatings and minimally invasive instruments. Its products span high-growth clinical segments including sports medicine, trauma repair and cardiovascular surgery. For Novanta, whose heritage lies in laser and photonics systems, the acquisition brings intellectual-property-protected consumables that are used repeatedly rather than sold once, changing the shape of its cash flows.
The deal is being sold by Arlington Capital Partners, the private equity owner that built out Riverpoint's manufacturing footprint. That footprint includes FDA-registered facilities in the United States and Costa Rica, giving Novanta regional production capacity and a hedge against supply-chain disruption.
The Financial Reshaping
Novanta expects the acquisition to roughly double its recurring medical consumables revenue to about $300 million and lift medical end-market exposure to close to 60% of total revenue. Management framed the move as a strategic pivot toward predictable, higher-margin income streams that are less exposed to the capital-equipment cycles that have historically driven photonics demand.
- Upfront consideration: $1.2 billion in cash
- Milestone payment: up to $250 million due by early 2027
- Added addressable market: an estimated $2 billion across surgical segments
- Expected close: third quarter of 2026
- Manufacturing: FDA-registered sites in the U.S. and Costa Rica
Financing and Leverage
Novanta is funding the purchase through a combination of cash on hand, existing credit facilities and a recent $300 million equity raise. To accommodate the deal, the company amended its credit agreement to permit higher leverage tied to this designated acquisition. Executives said the elevated leverage is expected to be temporary, with deleveraging supported by the target's cash generation.
The company told investors it expects the acquisition to be immediately accretive to 2026 adjusted earnings per share, and to lift revenue growth, margins and cash flow by 2027 as integration progresses.
Strategic Context
The transaction deepens Novanta's existing original-equipment-manufacturer relationships, since several of its surgical-device customers already source components across the two portfolios. By owning more of the consumables value chain, Novanta aims to reduce supply-chain risk for those partners while strengthening its competitive position in advanced surgical technology.
Analysts have noted that the deal fits a broader pattern of component and photonics suppliers moving downstream into recurring medical revenue, where valuations reward predictable consumable sales over lumpier equipment orders. The addition of regional manufacturing capacity also aligns with customer preferences for nearshored, redundant supply.
What to Watch
With closing targeted for the third quarter of 2026, attention now turns to regulatory clearance and integration execution. Key questions include how quickly Novanta can cross-sell Riverpoint's consumables through its existing channels, whether the milestone payment is triggered, and how rapidly the company brings leverage back within its long-term targets. For a business long defined by its photonics roots, the acquisition represents a decisive step toward becoming a recurring-revenue medical supplier.